Vivimed Labs aims to cash in on Uquifa buy

15 Dec 2011 Evaluate

Vivimed Labs is aiming to take advantage of global market potential for formulations post its acquisition of Spain-based active pharmaceutical ingredients maker, Uquifa. The company will facilitate Uquifa's active pharmaceutical ingredients' capacity, which will complement its formulations business with cost competitiveness.

Through shifting Uquifa's pharma ingredients production to India the Hyderabad-based company is going for backward integration. Its API facilities coming up at pharma special economic zone at Visakhaptanam and Bidar in Karnataka will help the company in formulations. Another plant to make finished dosages is also being set up exclusively for regulated markets at Choutuppal.

The combined investment in these plants is about Rs 190 crore. All of them should begin production by end of next financial year. The company expects to double its turnover to Rs 1,000 crore by end of next financial year with an equal share of specialty chemicals and pharmaceuticals in revenue.

Vivimed Labs Share Price

5.75 0.00 (0.00%)
31-Jul-2023 18:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×